Literature DB >> 29130486

RTP801 is a critical factor in the neurodegeneration process of A53T α-synuclein in a mouse model of Parkinson's disease under chronic restraint stress.

Zhao Zhang1, Shi-Feng Chu1, Sha-Sha Wang1,2, Yi-Na Jiang3, Yan Gao1, Peng-Fei Yang1, Qi-Di Ai3, Nai-Hong Chen1,3,4,2.   

Abstract

BACKGROUND AND
PURPOSE: Recently, the incidence of Parkinson's disease has shown a tendency to move to a younger population, linked to the constantly increasing stressors of modern society. However, this relationship remains obscure. Here, we have investigated the contribution of stress and the mechanisms underlying this change. EXPERIMENTAL APPROACH: Ten-month-old α-synuclein A53T mice, a model of Parkinson's disease (PD), were treated with chronic restraint stress (CRS) to simulate a PD-sensitive person with constant stress stimulation. PD-like behavioural tests and pathological changes were evaluated. Differentiated PC12-A53T cells were treated with corticosterone in vitro. We used Western blot, microRNA expression analysis, immunofluorescence staining, dual luciferase reporter assay and HPLC electrochemical detection to assess cellular and molecular networks after stress treatment. In vivo, stereotaxic injection of shRNA lentivirus was used to confirm our in vitro results. KEY
RESULTS: The protein RTP801 is encoded by DNA-damage-inducible transcript 4, and it was specifically increased in dopaminergic neurons of the substantia nigra after CRS treatment. RTP801 was post-transcriptionally inhibited by the down-regulation of miR-7. Delayed turnover of RTP801, through the inhibition of proteasome degradation also contributed to its high content. Elevated RTP801 blocked autophagy, thus increasing accumulation of oligomeric α-synuclein and aggravating endoplasmic reticulum stress. RTP801 inhibition alleviated the symptoms of neurodegeneration during this process. CONCLUSIONS AND IMPLICATIONS: RTP801 is a promising target for the treatment of PD, especially for PD-sensitive patients who live under increased social pressure. Down-regulation of RTP801 could inhibit the current tendency to an earlier onset of PD.
© 2017 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29130486      PMCID: PMC5786460          DOI: 10.1111/bph.14091

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  54 in total

1.  Charting of type II glucocorticoid receptor-like immunoreactivity in the rat central nervous system.

Authors:  R S Ahima; R E Harlan
Journal:  Neuroscience       Date:  1990       Impact factor: 3.590

2.  Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle.

Authors:  Noriaki Shimizu; Noritada Yoshikawa; Naoki Ito; Takako Maruyama; Yuko Suzuki; Sin-ichi Takeda; Jun Nakae; Yusuke Tagata; Shinobu Nishitani; Kenji Takehana; Motoaki Sano; Keiichi Fukuda; Makoto Suematsu; Chikao Morimoto; Hirotoshi Tanaka
Journal:  Cell Metab       Date:  2011-02-02       Impact factor: 27.287

3.  Impairment of dopaminergic system function after chronic treatment with corticotropin-releasing factor.

Authors:  Emanuela Izzo; Pietro Paolo Sanna; George F Koob
Journal:  Pharmacol Biochem Behav       Date:  2005-08       Impact factor: 3.533

4.  Treatment with a γ-ketoaldehyde scavenger prevents working memory deficits in hApoE4 mice.

Authors:  Sean S Davies; Chris Bodine; Elena Matafonova; Brooke G Pantazides; Nathalie Bernoud-Hubac; Fiona E Harrison; Sandra J Olson; Thomas J Montine; Venkataraman Amarnath; L Jackson Roberts
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

5.  Type II corticosteroid receptor-like immunoreactivity in the rat cerebellar cortex: differential regulation by corticosterone.

Authors:  R S Ahima; C N Tagoe; R E Harlan
Journal:  Neuroendocrinology       Date:  1992-06       Impact factor: 4.914

6.  Cortisol is higher in parkinsonism and associated with gait deficit.

Authors:  A Charlett; R J Dobbs; A G Purkiss; D J Wright; D W Peterson; C Weller; S M Dobbs
Journal:  Acta Neurol Scand       Date:  1998-02       Impact factor: 3.209

7.  Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor.

Authors:  L A Greene; A S Tischler
Journal:  Proc Natl Acad Sci U S A       Date:  1976-07       Impact factor: 11.205

8.  Salivary cortisol levels in Parkinson's disease and its correlation to risk behaviour.

Authors:  Atbin Djamshidian; Sean S O'Sullivan; Andrew Papadopoulos; Paul Bassett; Karen Shaw; Bruno B Averbeck; Andrew Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  2011-04-08       Impact factor: 10.154

9.  MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson's disease.

Authors:  Yan Zhou; Ming Lu; Ren-Hong Du; Chen Qiao; Chun-Yi Jiang; Ke-Zhong Zhang; Jian-Hua Ding; Gang Hu
Journal:  Mol Neurodegener       Date:  2016-04-16       Impact factor: 14.195

10.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands.

Authors:  Christopher Southan; Joanna L Sharman; Helen E Benson; Elena Faccenda; Adam J Pawson; Stephen P H Alexander; O Peter Buneman; Anthony P Davenport; John C McGrath; John A Peters; Michael Spedding; William A Catterall; Doriano Fabbro; Jamie A Davies
Journal:  Nucleic Acids Res       Date:  2015-10-12       Impact factor: 16.971

View more
  7 in total

Review 1.  Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?

Authors:  Pengfei Yang; Joel S Perlmutter; Tammie L S Benzinger; John C Morris; Jinbin Xu
Journal:  Ageing Res Rev       Date:  2019-11-22       Impact factor: 10.895

2.  RTP801 is a critical factor in the neurodegeneration process of A53T α-synuclein in a mouse model of Parkinson's disease under chronic restraint stress.

Authors:  Zhao Zhang; Shi-Feng Chu; Sha-Sha Wang; Yi-Na Jiang; Yan Gao; Peng-Fei Yang; Qi-Di Ai; Nai-Hong Chen
Journal:  Br J Pharmacol       Date:  2018-01-17       Impact factor: 8.739

Review 3.  Alpha-synuclein at the nexus of genes and environment: the impact of environmental enrichment and stress on brain health and disease.

Authors:  Zinah Wassouf; Julia M Schulze-Hentrich
Journal:  J Neurochem       Date:  2019-07-09       Impact factor: 5.372

4.  Pyk2 inhibition attenuates hypoxic-ischemic brain injury in neonatal mice.

Authors:  Jie Zhu; Shi-Feng Chu; Ye Peng; Dan-Dan Liu; Chen Chen; Wen-Xuan Jian; Hong-Shuo Sun; Zhong-Ping Feng; Zhao Zhang; Nai-Hong Chen
Journal:  Acta Pharmacol Sin       Date:  2021-07-05       Impact factor: 6.150

5.  Rg1 exerts protective effect in CPZ-induced demyelination mouse model via inhibiting CXCL10-mediated glial response.

Authors:  Yi-Xiao Dong; Shi-Feng Chu; Sha-Sha Wang; Ya-Juan Tian; Wen-Bin He; Yu-Sheng Du; Zhen-Zhen Wang; Xu Yan; Zhao Zhang; Nai-Hong Chen
Journal:  Acta Pharmacol Sin       Date:  2021-06-08       Impact factor: 6.150

Review 6.  Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease.

Authors:  Xian-Si Zeng; Wen-Shuo Geng; Jin-Jing Jia; Lei Chen; Peng-Peng Zhang
Journal:  Front Aging Neurosci       Date:  2018-04-17       Impact factor: 5.750

7.  Synaptic RTP801 contributes to motor-learning dysfunction in Huntington's disease.

Authors:  Núria Martín-Flores; Leticia Pérez-Sisqués; Jordi Creus-Muncunill; Mercè Masana; Sílvia Ginés; Jordi Alberch; Esther Pérez-Navarro; Cristina Malagelada
Journal:  Cell Death Dis       Date:  2020-07-30       Impact factor: 8.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.